Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia
- Molecular Medicine, Department of Medical Sciences, Uppsala University (Sweden)
- Department of Genetics and Pathology, Uppsala University Hospital (Sweden)
- Hematology Section, Department of Medical Sciences, Uppsala University Hospital (Sweden)
- Department of Medicine, Hematology Section, Umea University Hospital (Sweden)
- Department of Molecular Medicine and Surgery, Clinical Genetics Unit, Karolinska Institute, 171 76 Stockholm (Sweden)
Using a quantitative single nucleotide polymorphism (SNP) assay we have investigated the changes in the expression of the BCR-ABL1 oncogene relative to the wild-type ABL1 and BCR alleles in cells from chronic myeloid leukemia (CML) patients not responding to therapy. The results show a progressive increase in the BCR-ABL1 oncogene expression at the expense of decreased expression of the ABL1 allele, not involved in the fusion. No relative changes in the expression of the two BCR alleles were found. These results demonstrate that allele-specific changes in gene expression, with selective, progressive silencing of the wild-type ABL1 allele in favor of the oncogenic BCR-ABL1 allele occur in CML patients with therapy-resistant disease.
- OSTI ID:
- 21043624
- Journal Information:
- Biochemical and Biophysical Research Communications, Vol. 366, Issue 3; Other Information: DOI: 10.1016/j.bbrc.2007.12.029; PII: S0006-291X(07)02658-7; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
- Country of Publication:
- United States
- Language:
- English
Similar Records
Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance